Pharmacological profile of risperidone
Ereshefsky, L.; Lacombe, S.
Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie 38(Suppl 3): S80-S88
1993
ISSN/ISBN: 0706-7437 PMID: 7504573 Document Number: 414094
The pharmacodynamics and pharmacokinetics of risperidone, an important atypical antipsychotic drug with potent serotonin-5-HT2 and dopamine-D2 receptor blocking effects, are presented. The pharmacology of atypical versus typical antipsychotic drugs is discussed in the contest of a pathophysiological conceptualization for schizophrenia which incorporates a parkinsonian model with an important role for serotonin and excitatory amino acid neurotransmission. In the normal therapeutic dose range, risperidone displays dose-linear pharmacokinetics in humans and reaches steady-state within 24 hours. Risperidone metabolism yields a active metabolite, 9-OH-risperidone, that has a similar pharmacological profile to the patient compound and therefore contributes to the clinical efficacy of the drug.